Proline/arginine-rich end leucine-rich repeat protein (PRELP) belongs to the small leucine-rich proteoglycan (SLRP) family, normally expressed in extracellular matrix of collagen-rich tissues. We have previously reported on another SLRP, fibromodulin (FMOD) in patients with chronic lymphocytic leukemia (CLL). PRELP is structurally similar to FMOD with adjacent localization on chromosome 1 (1q32.1). As cluster-upregulation of genes may occur in malignancies, the aim of our study was to analyze PRELP expression in CLL. PRELP was expressed (RT-PCR) in all CLL patients (30/30), as well as in some patients with mantle cell lymphoma (3/5), but not in healthy donor leukocytes (0/20) or tumor samples from other hematological malignancies (0/35). PRELP was also detected in CLL cell-lines (4/4) but not in cell-lines from other hematological tumors (0/9). PRELP protein was detected in all CLL samples but not in normal leukocytes. Deglycosylation experiments revealed a CLL-unique 38 kDa core protein, with an intact signal peptide. This 38 kDa protein was, in contrast to the normal 55 kDa size, not detected in serum which, in combination with the uncleaved signal peptide, suggests cellular retention. The unique expression of a 38 kDa PRELP in CLL cells may suggest involvement in the pathobiology of CLL and merits further studies.
Introduction
The pathobiology of chronic lymphocytic leukemia (CLL) has become an increasingly explored area of research. In addition to understanding the role of the microenvironment, one of the major goals has been to identify genes involved in the pathogenesis of the disease. In 2001, gene expression profiling revealed, among others, fibromodulin (FMOD) as one of the most overexpressed genes in CLL compared to memory B cells of healthy donors. [1] FMOD is a member of the small leucine-rich proteoglycan family (SLRP) and is normally expressed in collagen-rich tissues. We demonstrated that FMOD was expressed at the gene and protein level in CLL and mantle cell lymphoma (MCL). [2] This unexpected finding of an aberrantly expressed extracellular matrix protein raised the question whether also other SLRP family members might be expressed in CLL.
Overexpression of genes in tumor cells might be due to epigenetic regulations, which may span a cluster of closely located genes. The proline/arginine-rich end leucine-rich repeat protein (PRELP) is structurally similar to FMOD and is located about 80 kb 39-proximal to FMOD on chromosome 1q32.1. [3] Human PRELP has been reported to have a molecular weight (MW) of 55 kDa and is normally expressed in the extracellular matrix of connective tissues, preferentially in cartilage, lung, kidney, skin, and tendon. [4, 5] The function of PRELP is unclear, but the interactions between PRELP and collagen type I and II as well as heparin and heparan sulphate [6, 7] suggest that PRELP may be a molecule anchoring basement membranes to connective tissue. [7] Following our previous studies on FMOD [2] and ROR1 [8] in CLL, both located on chromosome 1, the present study was undertaken to explore the gene and protein expression of PRELP in CLL and other hematological malignancies, in our endeavour to explore uniquely expressed molecules in CLL which may play a role in the pathobiology of the disease.
Materials and Methods

Patients and controls
Diagnosis of CLL and other hematological malignancies was established using the WHO classification of hematopoetic and lymphoid malignancies and the modified NCI criteria. [9] Clinical characteristics of the CLL patients are shown in Table 1 . Progressive and non-progressive CLL was defined as recommended by the IWCLL criteria. [10] Heparinized blood containing tumor cells was collected from patients with CLL (n = 30), MCL (n = 5), hairy cell leukemia (HCL) (n = 2), B-cell prolymphocytic leukemia (B-PLL) (n = 2), Tcell prolymphocytic leukemia (T-PLL) (n = 4), chronic myelogenous leukemia (CML) (n = 5), acute myelogenous leukemia (AML) (n = 5) and acute lymphoblastic leukemia (ALL) (n = 10). Bone marrow tumor cells were obtained from patients with multiple myeloma (MM) (n = 6), and follicular lymphoma (FL) (n = 2). Blood was also drawn from healthy control donors (n = 20). Serum was collected from CLL patients (n = 8) and healthy controls (n = 8).
All samples were collected with written informed consent of the patients and approval from the regional ethics committee (The regional ethical review board in Stockholm, www.epn.se).
Hematological cell lines
Four CLL cell lines and nine cell lines derived from a variety of other hematological malignancies were also studied; CLL (EHEB, I83-E95, 232-B4, WAC3-CD5), MM (LP-1), T-cell leukemia (SKW3), ALL (HUT-78, HPB-ALL, MOLT-4, JURKAT), AML (HL60), CML (K562), and NK cell lymphoma (YT). EHEB and YT were obtained from DSMZ (Braunschweig, Germany). The other CLL cell lines (I83-E95, 232-B4, WAC3-CD5) [11, 12] were a kind gift from Prof. Anders Rosén (Linköping University, Sweden) and Prof. Kenneth Nilsson (Uppsala University, Sweden).
The remaining cell lines were provided by the National Cell Bank of Iran (NCBI, Pasteur Institute of Iran, Tehran, Iran). All cell lines were adapted to grow in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), L-glutamine (2 mM), penicillin (100 U/ml) and streptomycin (100 mg/ml) (Gibco, Paisley, Scotland).
Isolation of cells
Peripheral blood mononuclear cells (PBMC) from normal donors and leukemic cells from blood and bone marrow were isolated using Ficoll-Paque Plus (GE Healthcare, Buckinghamshire, UK) density-gradient centrifugation. Normal T and B lymphocytes were purified be negative selection using MACS beads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's instructions. For isolation of CLL T-cells, the CLL PBMCs were depleted by filtration through a nylon wool column (Biotest, Breiech, Germany). The effluent cells were further enriched by negative selection using MACS beads. The purity of the isolated populations was tested by direct immunofluorescence using monoclonal antibodies against CD3, CD19, and CD14 (BD Biosciences, San Jose, CA, USA). The purity was .90% for normal B cells and .70% for normal T cells, and .80% for CLL T-cells. Granulocytes were recovered from the top of the erythrocyte layer. Erythrocytes were lysed by hypo-osmosis in cold water. More than 98% of the nucleated cells were granulocytes as evaluated by immunocytology.
RT-PCR and quantitative PCR (q-PCR) amplification of PRELP mRNA
Total RNA was extracted from tumor cells and normal PBMC using PureLink TM RNA Mini Kit (Ambion, Carlsbad, CA, USA) according to the manufacturer's instruction. First strand cDNA was synthesized using SuperScript TM III Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol.
PCR amplification was performed using PRELP specific primers (Table 2) . Briefly, 25 ml of PCR reaction mixture was prepared using 2.5 ml of 106 buffer, 2 ml of 25 mM MgCl 2 , 1.5 ml dNTPs (10 mM), 5 pmol of each primer and 1 unit of Ampli-Taq Gold DNA polymerase (Perkin-Elmer/Applied Biosystems, Boston, MA, USA). PCR was initiated by 1 cycle at 95uC for 10 min, followed by 35 cycles of 92uC; 30 sec, 60uC; 30 sec, and 72uC; 30 sec leading to a 334 bp amplicon. To assure the specificity of primers, some PCR products were cloned into pGEM-T easy vector (Promega, Madison, WI, USA) and subjected to sequencing.
Quantitative q-PCR was performed using Taqman gene expression assay for PRELP (Applied Biosystems, assay ID# Hs00160431_m1). PCR reactions consisting of 1 mL cDNA, 1X TaqManH Universal PCR Master Mix, 0.2 mM TaqManH primerprobe mix were carried out in final volumes of 20 mL using an ABI Prism 7900 Sequence Detection System (Applied Biosystems). Reactions were initiated with a 10 minute incubation at 95uC followed by 40 cycles of 95uC for 15 seconds and 60uC for 60 seconds. The analysis was based on individual samples run in triplicates, of which a mean Ct value was calculated. The expression of PRELP was then normalized against the housekeeping gene GAPDH (Applied Biosystem assay #Hs02758991_g1) and relative quantities were determined by the comparative Ct (DCt) method. Untreated*** 67 *for definition, see ref [10] . **test performed at relapse/progression prior to initiation of salvage therapy. ***Among 20 untreated patients, 11 were indolent and 9 were progressive/ symptomatic but tested prior to first-line therapy. doi:10.1371/journal.pone.0067601.t001
Production of PRELP protein
Due to lack of commercially available PRELP protein, we established a yeast expression system based on cDNA from PBMC of CLL patients (n = 10) that were pooled, and a full-length PRELP transcript was PCR-amplified. The PCR product was cloned into pGEM-T easy vector and subcloned into pGAPZa-A vector for yeast P. pastoris (Invitrogen). The recombinant plasmids were selected for sequencing. After selecting an in-frame clone, the construct was linearized using AvrII restriction enzyme and transfected into P. pastoris strain SMD1168 (Invitrogen). The colonies were screened by gene specific PCR amplification and positive clones were selected for protein production. The supernatant of a 72 h cultured yeast clone was collected and concentrated up to 30 times using Amicon Ultra-15 Centrifugal Filter Units (Millipore Corporation, Bedford, MA, USA).
For expression in mammalian cells, a full-length PRELP cDNA clone (transcript variant 1, SC111673, TrueClones, OriGene Technologies, Inc. Rockville, MD, USA) was subcloned into NotI site of a mammalian expression vector pCMV6-Neo (OriGene Technologies). After selection and sequencing of an in-frame clone, the plasmid was transfected into mouse SP2/0 cell line to obtain stable transfectants using jetPEI TM transfection reagent (Polyplus-transfection TM , Illkirch, France). Cells were harvested, washed extensively and lysate prepared as described for Western blot.
Chemical deglycosylation of PRELP protein
Recombinant PRELP protein produced in yeast was subjected to chemical deglycosylation using trifluoromethanesulfonic acid (TFMS) (Sigma, St Louis, MO, USA) and anisole (Fluka, Sigma). TFMS removes all carbohydrates chains from glycoproteins regardless of linkage and composition. [13] 250 ml of yeast culture supernatant was precipitated in 100% ethanol at 220uC over night in two separate tubes. Protein pellets were collected by centrifugation at 15000 g for 20 min, washed in 95% ethanol, collected by centrifugation and air-dried for 1 h. 200 ml TFMS and anisole (9:1) was added to the dry pellets and the samples were incubated on ice for 2 and 4 h, respectively. The reaction was stopped by the addition of 2 M Tris base (pH 8) until pH reached 6. The samples were dialysed against 10 mM phosphate buffer for 24 h, concentrated 20 times in Amicon Ultra-15 Centrifugal Filter Units (Millipore Corp.) and then subjected to Western blot.
Anti-PRELP poly-and monoclonal antibodies
In the absence of commercially available anti-PRELP antibodies recognizing PRELP in CLL, one rabbit anti-PRELP polyclonal antibody (pAb) was produced against a 19-mer peptide (CGGKARAKGGFRLLQSVVI) purchased from Thermo Electron Corporation GmbH (Ulm, Germany) of which the 9 last amino acids correspond to the carboxy-terminal (C-terminal) part of human PRELP. [4] The antibody was purified by affinity chromatography.
In addition, two mouse anti-PRELP monoclonal antibodies (mAbs) were produced using Keyhole limpet hemocyanin (KLH)-conjugated PRELP-peptides following a standard protocol with minor modifications. [14] One mouse mAb was generated against the carboxy-terminal peptide (CGGKARAKGGFRLLQSVVI). The other mAb was raised against the N-terminal region for which a 20-mer peptide (MRSPLCWLLPLLILASVAQG) (Thermo Electron) covering the whole signal sequence was used.
Western blot
Cell lysates were prepared as described with minor modifications. [15] Briefly, 50610 6 cells were lysed in 1 mL of buffer containing 0.2% triton-X, 130 mM HEPES, 4 mM MgCl 2 , 10 mM EGTA with 2% proteinase inhibitor cocktail (Sigma). After 1 h incubation on ice, lysates were centrifuged at 2500 rpm for 5 min and the soluble fraction was collected. The protein concentration was measured by Bio-Rad Protein Assay according to the manufacturer's instructions (Bio-Rad Laboratories, Hercules, CA, USA). Cell lysate (20 mg), serum (dil 1:50), and yeast supernatants were subjected to Western blot using a 10% NuPAGE Bis-Tris gel (Invitrogen) at 120 V for 3 h under reducing conditions. Resolved proteins were transferred onto Immobilon-P PVDF membrane (Millipore Corp.) in a MiniTransblot Cell (Invitrogen). Non-specific antibody binding was blocked by incubating the membranes at room temperature for 1,5 h with 5% non-fat milk (Semper, Stockholm, Sweden) in PBS plus 0.05% Tween 20 (PBS-T). The membranes were incubated with 10 mg/ml of anti-PRELP rabbit polyclonal or mouse monoclonal antibody over night at +4uC and a secondary horseradish peroxidise (HRP)-conjugated goat anti-rabbit or rabbit anti-mouse antibody (DakoCytomation, Glostrup, Denmark) for 1.5 h at room temperature. 4615 min washings in PBS-T followed both incubations. Antibody-reactive bands were visualized using Amersham Enhanced Chemiluminescence ECL TM system (GE Healthcare). To verify equal loading of samples, filters were stripped in a buffer containing 62.5 mM Tris-HCL, 2% SDS, 100 mM Mercaptoethanol (Sigma) at 50uC for 30 min. Following 3615 min washing in PBS-T, the membranes were re-probed with 2.5 mg/ml of a mouse anti-b-actin monoclonal antibody (Sigma).
Statistical analysis
The results are shown as mean 6 SEM and statistical analysis was performed with a T-test or Anova multivariant analysis together with post hoc Tukey test. Results
PRELP gene expression
The expression of PRELP mRNA was tested by RT-PCR in tumor cells from CLL patients and other hematological malignancies as well as in PBMC and leukocyte subsets from healthy control donors. First, we tested PRELP mRNA expression in PBMC from CLL patients and healthy donors. PBMC from all CLL patients (n = 30) expressed PRELP at the mRNA level irrespective of clinical phase (non-progressive/progressive) (Figure 1 Supplementary Table S1 . Sequencing of cDNA from CLL patients (n = 10) revealed no major mutations in the PRELP gene (data not shown).
Next, we tested PRELP mRNA expression in other hematological malignancies. PRELP was expressed in tumor cells of some MCL patients (3/5) but not in FL (0/2), T-or B-PLL (0/6), HCL (0/2), MM (0/6), CML (0/5), AML (0/5), and ALL (0/10) (Supplementary Table S1 ).
Thereafter, we tested cell lines and found that PRELP mRNA was expressed in all four CLL cell lines (EHEB, I83-E95, 232-B4, WAC3-CD5) but not in cell lines derived from myeloma (0/1), T cell leukemia (0/1), ALL (0/4), AML (0/1), CML (0/1), and NK cell lymphoma (0/1) (Supplementary Table S2) .
By q-PCR, the expression of PRELP mRNA was quantified in relation to the housekeeping gene GAPDH. The relative expression of PRELP was significantly higher in CLL patients (n = 30) compared to healthy control donors (n = 12) (p,0,0001). Also, dividing the CLL samples into progressive and nonprogressive resulted in higher relative expression of PRELP in both groups compared to healthy donors (p,0,001 respectively). There was no difference in PRELP expression between progressive and non-progressive CLL (Figure 2 ).
Specificity of anti-PRELP antibodies
The specificity of our own-produced anti-PRELP poly-and monoclonal antibodies was tested against recombinant PRELP protein expressed in SP2/0 mouse cell line ( Figures 3A-C) . Cells transfected with pCMV6-Neo vector alone were used as a negative control. The MW of normal, full-length glycosylated PRELP protein is 55 kDa. [4] In Western blot, the C-terminal rabbit polyclonal anti-PRELP antibody recognized a major band of 55-58 kDa but also three additional bands of 38, 44, and 48 kDa respectively. The mouse monoclonal anti-PRELP antibodies (Cterminal as well as N-terminal) recognized a 38 kDa PRELP band only, suggesting different epitope binding by our panel of ownproduced pAb and mAb against PRELP. 
PRELP protein expression in CLL cells
Having confirmed the PRELP specificity of our anti-PRELP pAb and mAb, we thereafter used PBMC from CLL patients (n = 30) and analysed PRELP protein expression by Western blot. In tumor cell lysates, a band of 38 kDa was detected in all CLL patients and all four CLL cell lines. This 38 kDa band was recognized both by the C-terminal and the N-terminal antibodies eliminating the possibility that the 38 kDa fragment is a degradation product. In contrast, the PRELP protein was not detected in PBMC of healthy control donors (n = 10) (Figure 4) .
Deglycosylation of the PRELP protein
Unmodified yeast-derived PRELP had a MW of about 100 kDa ( Figure 5 ). To explore the nature of the various PRELP bands found in our initial experiments ( Figure 3A-C) , we performed chemical deglycosylation using TFMS and anisole. The results are shown in Figure 5 . After 2 h of treatment, bands in the region of 51-64 kDa appeared. After 4 h, a band of 38 kDa was seen, probably representing a completely deglycosylated PRELP protein (which is in line with the 38 kDa size band found in CLL cells and CLL cell lines shown in Figure 4 ).
PRELP protein expression in serum
We also analyzed serum from 8 CLL patients and 8 healthy control donors by Western blot. All serum samples (both CLL and healthy controls) showed two bands, 50 and 58 kDa (Figure 6 ), corresponding to full-length PRELP. [4] The 38 kDa PRELP protein was not detected in serum from either patients or normal donors.
Discussion
The present study demonstrates that the SLRP family member PRELP seems to be exclusively expressed in CLL cells and CLL cell lines as well as in some patients with MCL. Other haematological malignancies and cell lines as well as PBMC of normal donors did not express PRELP. Strong polyclonal activation (PMA/ionomycin) of normal B and T lymphocytes did not induce PRELP expression (data not shown), suggesting that the expression in CLL might reflect a constitutive tumorrelated aberration in vivo.
We related the expression of PRELP to age, gender, leukemic cell count, genomic aberrations (13q del, 17p del, trisomy12) and previous treatment but no relation could be found. Also, RAI stage and CD38 expression analysed in a subset of patients showed no correlation to PRELP expression (data not shown). Zap-70 and IgHV mutational status were not tested. PRELP is normally secreted into the extracellular matrix compartment but its exact function is not clearly known. The 50 and 58 kDa PRELP proteins detected in serum from both CLL patients and healthy controls may correspond to mature glycosylated PRELP [4] , and might be produced by fibroblasts in the connective tissues. However, in the CLL cell lysates, a unique 38 kDa PRELP protein was identified. This 38 kDa protein was detected by both C-terminal and N-terminal anti-PRELP antibodies suggesting that the 38 kDa protein is not a cleavageor degradation product. This is further supported by deglycosylation experiments that reduced all PRELP bands with the exception for the 38 kDa band. Mutation analysis of the PRELP gene in CLL did not reveal any substantial nucleotide aberrations. These findings, in combination with only two coding exons, make splice variants or truncation unlikely.
The own produced anti-PRELP N-terminal antibody was directed against the signal peptide and recognized a 38 kDa CLL-specific PRELP band, indicating that the signal peptide was not cleaved off. The presence of an intact signal peptide may suggest retention of the 38 kDa PRELP in the cytosol. This is further supported by the finding that the 38 kDa PRELP protein was not detected in serum and thus probably not secreted by CLL cells. Rapid degradation of the 38 kDa PRELP in serum by proteases could however not be excluded.
Recombinant PRELP expressed in SP2/0 cells, was detected by our polyclonal C-terminal antibody as weak bands of 38, 44, 48 kDa and a major band of 55-58 kDa. This is assumed to represent varying degrees of glycosylation. Our anti-PRELP mAbs, recognized however only the 38 kDa band. An explanation might be that our mAbs recognized epitopes that are hidden in the mature PRELP three-dimensional folding. This is the first report connecting PRELP with CLL (and partly to MCL). There are reports linking other SLRPs to cancer. [16, 17] We have previously reported on the unique CLL expression of the closely related SLRP FMOD. [2] SLRPs are normally secreted proteins that mediate their functions by binding to membrane receptors or extracellular matrix proteins. However, other locations and functions have been reported. PRELP has been shown to bind and inhibit NF-kappa B activity in the nucleus of osteoclasts. [18] Our findings suggest the presence of a predominant, nonsecreted unglycosylated 38 kDa variant of PRELP in CLL cells. The specific expression of another structurally related proteoglycan, FMOD [2] , in CLL as well as a third SLRP, opticin (OPTC) (own unpublished observation), located in close proximity to FMOD and PRELP on chromosome 1 (1q32) may suggest a broader role of proteoglycans in CLL. Functional characterization of proteoglycans in CLL is warranted to understand their biological importance in the pathogenesis of CLL. 
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